- Home
- NTRB vs LTRN Comparison
NTRB vs LTRN Comparison
Compare NTRB & LTRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NTRB | LTRN |
|---|---|---|
| Founded | 2016 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.0M | 49.9M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | NTRB | LTRN |
|---|---|---|
| Price | $4.41 | $3.45 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $13.00 | ★ $25.00 |
| AVG Volume (30 Days) | ★ 65.4K | 59.4K |
| Earning Date | 12-11-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,278,321.00 | N/A |
| Revenue This Year | $30.17 | N/A |
| Revenue Next Year | $3,394.36 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 12.69 | N/A |
| 52 Week Low | $3.90 | $2.55 |
| 52 Week High | $11.78 | $6.12 |
Technical Indicators
Market Signals| Indicator | NTRB | LTRN |
|---|---|---|
| Relative Strength Index (RSI) | 41.12 | 52.83 |
| Support Level | $4.33 | $2.90 |
| Resistance Level | $4.61 | $3.72 |
| Average True Range (ATR) | 0.41 | 0.26 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 2.88 | 75.33 |
Price Performance
Historical ComparisonAbout NTRB Nutriband Inc.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.
About LTRN Lantern Pharma Inc.
Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.